Der Schlaganfall beim jungen Menschen

Lernziele

Umfangreiche Kenntnisse der

neurologischen, kardiologischen und allgemeinmedizinischen Diagnostik bei juvenilem Schlaganfall

Literatur

• 1 Nedeltchev K, de Maur T A, Georgiadis D et al. Ischaemic stroke in young adults: predictors of outcome and recurrence.  J Neurol Neurosurg Psychiatry. 2005;  76 191-195
• 2 Bogousslavsky J, Pierre P. Ischemic stroke in patients under age 45.  Neurol Clin. 1992;  10 113-124
• 3 Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.  J Neurol. 2005;  252 1155-1166
• 4 Kittner S J, Stern B J, Wozniak M et al. Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study.  Neurology. 1998;  50 890-894
• 5 Reynolds H R, Tunick P A, Kronzon I. Role of transesophageal echocardiography in the evaluation of patients with stroke.  Curr Opin Cardiol. 2003;  18 340-345
• 6 Nabavi D G, Allroggen A, Ringelstein E B. [Juvenile ischemic brain infarction. Clinical aspects, etiology spectrum, diagnosis and therapy].  Nervenarzt. 2004;  75 167-186
• 7 Manabe H, Yonezawa K, Kato T et al. Incidence of intracranial arterial dissection in non-emergency outpatients complaining of headache: preliminary investigation with MRI / MRA examinations.  Acta Neurochir Suppl. 2010;  107 41-44
• 8 Diener H C, Putzki N, Berlit P et al. Leitlinien für Diagnostik und Therapie in der Neurologie.. 4th ed. Stuttgart: Thieme; 2008
• 9 Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection.  Cochrane Database Syst Rev. 2000;  CD000255
• 10 Sheikh S I, Singhal A B. Extension of „roller coaster dissection” after tissue plasminogen activator.  AJNR Am J Neuroradiol. 2010;  31 E4
• 11 Perdu J, Boutouyrie P, Lahlou-Laforet K et al. [Vascular Ehlers-Danlos syndrome].  Presse Med. 2006;  35 1864-1875
• 12 Schievink W I. Cerebrovascular Involvement in Ehlers-Danlos Syndrome.  Curr Treat Options Cardiovasc Med. 2004;  6 231-236
• 13 Schievink W I, Limburg M, Oorthuys J W et al. Cerebrovascular disease in Ehlers-Danlos syndrome type IV.  Stroke. 1990;  21 626-632
• 14 Byers P H. Ehlers-Danlos syndrome type IV: a genetic disorder in many guises.  J Invest Dermatol. 1995;  105 311-313
• 15 North K N, Whiteman D A, Pepin M G et al. Cerebrovascular complications in Ehlers-Danlos syndrome type IV.  Ann Neurol. 1995;  38 960-964
• 16 Pepin M, Schwarze U, Superti-Furga A et al. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.  N Engl J Med. 2000;  342 673-680
• 17 Schievink W I, Piepgras D G, Earnest F T et al. Spontaneous carotid-cavernous fistulae in Ehlers-Danlos syndrome Type IV. Case report.  J Neurosurg. 1991;  74 991-998
• 18 Sandok B A. Fibromuscular dysplasia of the internal carotid artery.  Neurol Clin. 1983;  1 17-26
• 19 Osborn A G, Anderson R E. Angiographic spectrum of cervical and intracranial fibromuscular dysplasia.  Stroke. 1977;  8 617-626
• 20 Corrin L S, Sandok B A, Houser O W. Cerebral ischemic events in patients with carotid artery fibromuscular dysplasia.  Arch Neurol. 1981;  38 616-618
• 21 Singhal A B. Cerebral vasoconstriction syndromes.  Top Stroke Rehabil. 2004;  11 1-6
• 22 Kraemer M, Berlit P. Reversibles zerebrales Vasokonstriktionssyndrom versus zerebrale Vaskulitis.  Der Nervenarzt. 2010;  epub ahead of print
• 23 Singhal A B. Thunderclap headache, reversible cerebral arterial vasoconstriction, and unruptured aneurysms.  J Neurol Neurosurg Psychiatry. 2002;  73 96; author reply 96-97
• 24 Calabrese L H, Dodick D W, Schwedt T J et al. Narrative review: reversible cerebral vasoconstriction syndromes.  Ann Intern Med. 2007;  146 34-44
• 25 Singhal A B, Koroshetz W R, Caplan L R. Reversible cerebral vasoconstriction syndromes.. 2. ed. Cambridge University Press; 2010
• 26 Singhal A B, Topcuoglu M A, Dorer D J et al. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage.  Neurology. 2005;  64 1008-1013
• 27 Rosenbloom M H, Singhal A B. CT angiography and diffusion-perfusion MR imaging in a patient with ipsilateral reversible cerebral vasoconstriction after carotid endarterectomy.  AJNR Am J Neuroradiol. 2007;  28 920-922
• 28 Kraemer M, Berlit P. Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases.  Rheumatol Int. 2009;  201 1471-1476
• 29 Kraemer M, Berlit P. Primary central nervous system vasculitis: clinical experiences with 21 new European cases.  Rheumatol Int. 2009;  epub ahead of print
• 30 Salvarani C, Brown Jr R D, Calamia K T et al. Primary central nervous system vasculitis: analysis of 101 patients.  Ann Neurol. 2007;  62 442-451
• 31 Zuber M, Blustajn J, Arquizan C et al. Angiitis of the central nervous system.  J Neuroradiol. 1999;  26 101-117
• 32 Salvarani C, Brown Jr R D, Calamia K T et al. Primary CNS vasculitis with spinal cord involvement.  Neurology. 2008;  70 2394-2400
• 33 Goertz C, Wegner C, Bruck W et al. Primary angiitis of the CNS with pure spinal cord involvement: a case report.  J Neurol. 2010;  257 1762-1764
• 34 Berlit P. Isolated angiitis of the CNS and bacterial endocarditis: similarities and differences.  J Neurol. 2009;  256 792-795
• 35 Sloan M A, Kittner S J, Feeser B R et al. Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study.  Neurology. 1998;  50 1688-1693
• 36 Kraemer M, Berlit P. Primary central nervous system vasculitis and moyamoya disease: similarities and differences.  J Neurol. 2010;  257 816-819
• 37 Calabrese L H, Molloy E S, Singhal A B. Primary central nervous system vasculitis: progress and questions.  Ann Neurol. 2007;  62 430-432
• 38 Miller D H, Ormerod I E, Gibson A et al. MR brain scanning in patients with vasculitis: differentiation from multiple sclerosis.  Neuroradiology. 1987;  29 226-231
• 39 Iancu-Gontard D, Oppenheim C, Touze E et al. Evaluation of hyperintense vessels on FLAIR MRI for the diagnosis of multiple intracerebral arterial stenoses.  Stroke. 2003;  34 1886-1891
• 40 Kadkhodayan Y, Alreshaid A, Moran C J et al. Primary angiitis of the central nervous system at conventional angiography.  Radiology. 2004;  233 878-882
• 41 Hellmann D B, Roubenoff R, Healy R A et al. Central nervous system angiography: safety and predictors of a positive result in 125 consecutive patients evaluated for possible vasculitis.  J Rheumatol. 1992;  19 568-572
• 42 Moore P M. Diagnosis and management of isolated angiitis of the central nervous system.  Neurology. 1989;  39 167-173
• 43 Calabrese L H, Duna G F. Evaluation and treatment of central nervous system vasculitis.  Curr Opin Rheumatol. 1995;  7 37-44
• 44 Duna G F, Calabrese L H. Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system.  J Rheumatol. 1995;  22 662-667
• 45 Berlit P. Primary angiitis of the CNS – an enigma that needs world-wide efforts to be solved.  Eur J Neurol. 2009;  16 10-11
• 46 Aras R, da Matta J A, Mota G et al. Cerebral infarction in autopsies of chagasic patients with heart failure.  Arq Bras Cardiol. 2003;  81 411-416
• 47 Tipping B, de Villiers L, Candy S et al. Stroke caused by human immunodeficiency virus-associated intracranial large-vessel aneurysmal vasculopathy.  Arch Neurol. 2006;  63 1640-1642
• 48 Rabinstein A A. Stroke in HIV-infected patients: a clinical perspective.  Cerebrovasc Dis. 2003;  15 37-44
• 49 Calabrese L H. Vasculitis and infection with the human immunodeficiency virus.  Rheum Dis Clin North Am. 1991;  17 131-147
• 50 Danielsen A G, Weismann K, Jorgensen B B et al. Incidence, clinical presentation and treatment of neurosyphilis in Denmark 1980–1997.  Acta Derm Venereol. 2004;  84 459-462
• 51 Fritz V U, Bryer A. Stroke in persons infected with HIV.. In: Caplan L R Uncommon causes of stroke.. Cambridge: Cambridge Medicine; 2008
• 52 Weyand C M, Goronzy J J. Giant-cell arteritis and polymyalgia rheumatica.  Ann Intern Med. 2003;  139 505-515
• 53 Kraemer M, Metz A, Herold M et al. Reduction in jaw opening: a neglected symptom of giant cell arteritis.  Rheumatol Int. 2010;  epub ahead of print
• 54 Hashimoto Y, Tanaka M, Hata A et al. Four years follow-up study in patients with Takayasu arteritis and severe aortic regurgitation; assessment by echocardiography.  Int J Cardiol. 1996;  54 S173-176
• 55 Hata A, Noda M, Moriwaki R et al. Angiographic findings of Takayasu arteritis: new classification.  Int J Cardiol. 1996;  54 S155-163
• 56 Berlit P. [Cerebral vasculitis].  Nervenarzt. 2004;  75 817-828; quiz 829–830
• 57 Berlit P, Stueper B, Fink I et al. Behcet’s disease is associated with increased concentrations of antibodies against phosphatidylserine and ribosomal phosphoproteins.  Vasa. 2005;  34 176-180
• 58 Kramer M, Baumgartel M W, Neuen-Jacob E et al. [Myalgia in Neuro-Behcet’s disease. Medication side effects or expression of underlying disease].  Z Rheumatol. 2008;  67 232-236
• 59 Greenberg S M, Vonsattel J P, Stakes J W et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage.  Neurology. 1993;  43 2073-2079
• 60 Haan J, Bakker E, Jennekens-Schinkel A et al. Progressive dementia, without cerebral hemorrhage, in a patient with hereditary cerebral amyloid angiopathy.  Clin Neurol Neurosurg. 1992;  94 317-318
• 61 Haan J, Roos R A. Comparison between the Icelandic and Dutch forms of hereditary cerebral amyloid angiopathy.  Clin Neurol Neurosurg. 1992;  94 S82-83
• 62 Roos R A, Haan J. Function of amyloid and amyloid protein precursor.  Clin Neurol Neurosurg. 1992;  94 S1-3
• 63 Berlit P. The spectrum of vasculopathies in the differential diagnosis of vasculitis.  Semin Neurol. 1994;  14 370-379
• 64 Kramer M, Berlit P. [Moyamoya disease – a rare vasculopathy in Europeans].  Fortschr Neurol Psychiatr. 2010;  78 542-550; quiz 551
• 65 Kraemer M, Heienbrok W, Berlit P. Moyamoya disease in Europeans.  Stroke. 2008;  39 3193-3200
• 66 Earley C J, Kittner S J, Feeser B R et al. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study.  Neurology. 1998;  51 169-176
• 67 Wakai K, Tamakoshi A, Ikezaki K et al. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey.  Clin Neurol Neurosurg. 1997;  99 (S 02) S1-5
• 68 Ikeda K, Iwasaki Y, Kashihara H et al. Adult moyamoya disease in the asymptomatic Japanese population.  J Clin Neurosci. 2006;  13 334-338
• 69 Yonekawa Y, Ogata N, Kaku Y et al. Moyamoya disease in Europe, past and present status.  Clin Neurol Neurosurg. 1997;  99 (S 02) S58-60
• 70 Fukui M, Kono S, Sueishi K et al. Moyamoya disease.  Neuropathology. 2000;  20 S61-64
• 71 Roder C, Nayak N R, Khan N et al. Genetics of Moyamoya disease.  J Hum Genet. 2010;  55 711-716
• 72 Roder C, Peters V, Kasuya H et al. Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans.  Childs Nerv Syst. 2010;  epub ahead of print
• 73 Roder C, Peters V, Kasuya H et al. Analysis of ACTA2 in European Moyamoya disease patients.  Eur J Paediatr Neurol. 2010;  epub ahead of print
• 74 Roder C, Peters V, Kasuya H et al. Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients.  Acta Neurochir (Wien). 2010;  152 2153-2160
• 75 Inoue T K, Ikezaki K, Sasazuki T et al. Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease.  Clin Neurol Neurosurg. 1997;  99 (S 02) S234-237
• 76 Inoue T K, Ikezaki K, Sasazuki T et al. DNA typing of HLA in the patients with moyamoya disease.  Jpn J Hum Genet. 1997;  42 507-515
• 77 Achrol A S, Guzman R, Lee M et al. Pathophysiology and genetic factors in moyamoya disease.  Neurosurg Focus. 2009;  26 E4
• 78 Muroi C, Yonekawa Y, Khan N et al. Metabolic changes after H(2) 15O-positron emission tomography with acetazolamide in a patient with moyamoya disease: case report and review of previous cases.  J Neurosurg Anesthesiol. 2003;  15 131-139
• 79 Weber B, Westera G, Treyer V et al. Constant-infusion H(2)15O PET and acetazolamide challenge in the assessment of cerebral perfusion status.  J Nucl Med. 2004;  45 1344-1350
• 80 Khan N, Dodd R, Marks M P et al. Failure of Primary Percutaneous Angioplasty and Stenting in the Prevention of Ischemia in Moyamoya Angiopathy.  Cerebrovasc Dis. 2010;  31 147-153
• 81 Wohlrab J, Fischer M, Marsch W C. [Current diagnosis of Sneddon syndrome].  Dtsch Med Wochenschr. 2001;  126 725-728
• 82 Boesch S M, Plorer A L, Auer A J et al. The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study.  J Neurol Neurosurg Psychiatry. 2003;  74 542-544
• 83 de Aquino Gondim F A, Leacock R O, Subrammanian T A et al. Intracerebral hemorrhage associated with Sneddon’s syndrome: is ischemia-related angiogenesis the cause? Case report and review of the literature.  Neuroradiology. 2003;  45 368-372
• 84 Kraemer M, Berlit P. Cerebral haemorrhage as the presenting form of Sneddon’s syndrome.  Clin Neurol Neurosurg. 2008;  110 533
• 85 Kraemer M, Baumgaertel M W, Berlit P. Miscarriage, peripheral thromboses and aortic aneurysm in antiphospholipid-antibody-negative Sneddon’s syndrome.  J Neurol. 2007;  254 1599-1600
• 86 Kraemer M, Berlit P. Long-term course of antiphospholipid-antibody-negative Sneddon’s syndrome.  Clin Neurol Neurosurg. 2008;  110 1072
• 87 Hachulla E, Piette A M, Hatron P Y et al. [Aspirin and antiphospholipid syndrome].  Rev Med Interne. 2000;  21 (S 01) 83s-88s
• 88 Floel A, Imai T, Lohmann H et al. Therapy of Sneddon syndrome.  Eur Neurol. 2002;  48 126-132
• 89 Frances C, Piette J C. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus.  J Autoimmun. 2000;  15 139-143
• 90 Frances C, Papo T, Wechsler B et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients.  Medicine (Baltimore). 1999;  78 209-219
• 91 Khamashta M A, Cuadrado M J, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome.  N Engl J Med. 1995;  332 993-997
• 92 Kurth T. The association of migraine with ischemic stroke.  Curr Neurol Neurosci Rep. 2010;  10 133-139
• 93 Kurth T, Schurks M, Logroscino G et al. Migraine frequency and risk of cardiovascular disease in women.  Neurology. 2009;  73 581-588
• 94 Kurth T, Tzourio C. Migraine and cerebral infarct-like lesions on MRI: an observation, not a disease.  JAMA. 2009;  301 2594-2595
• 95 Savitz S I, Caplan L R. Migraine and Migraine-like conditions.. In: Caplan L R Uncommon causes of stroke.. Cambridge: Cambridge Medicine; 2008
• 96 Beda R D, Gill Jr E A. Patent foramen ovale: does it play a role in the pathophysiology of migraine headache?.  Cardiol Clin. 2005;  23 91-96
• 97 Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.  Nature. 1996;  383 707-710
• 98 Dichgans M, Mayer M, Uttner I et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases.  Ann Neurol. 1998;  44 731-739
• 99 Dichgans M, Filippi M, Bruning R et al. Quantitative MRI in CADASIL: correlation with disability and cognitive performance.  Neurology. 1999;  52 1361-1367
• 100 Dichgans M, Holtmannspotter M, Herzog J et al. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study.  Stroke. 2002;  33 67-71
• 101 Mikol J, Henin D, Baudrimont M et al. [Atypical CADASIL phenotypes and pathological findings in two new French families].  Rev Neurol (Paris). 2001;  157 655-667
• 102 Robinson W, Galetta S L, McCluskey L et al. Retinal findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil).  Surv Ophthalmol. 2001;  45 445-448
• 103 Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia.  Ann N Y Acad Sci. 1997;  826 213-217
• 104 Joutel A, Favrole P, Labauge P et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis.  Lancet. 2001;  358 2049-2051
• 105 Dichgans M, Petersen D. Angiographic complications in CADASIL.  Lancet. 1997;  349 776-777
• 106 Koga Y, Povalko N, Nishioka J et al. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes.  Ann N Y Acad Sci. 2010;  1201 104-110
• 107 Majamaa K, Turkka J, Karppa M et al. The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct.  Neurology. 1997;  49 1331-1334
• 108 Sue C M, Crimmins D S, Soo Y S et al. Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis.  J Neurol Neurosurg Psychiatry. 1998;  65 233-240
• 109 Sue C M, Quigley A, Katsabanis S et al. Detection of MELAS A3243G point mutation in muscle, blood and hair follicles.  J Neurol Sci. 1998;  161 36-39
• 110 Wozniak M A, Kittner S J, Tuhrim S et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke.  Stroke. 2010;  41 78-81
• 111 Topaloglu A K, Ashley G A, Tong B et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.  Mol Med. 1999;  5 806-811
• 112 Desnick R J, Wasserstein M P. Fabry disease: clinical features and recent advances in enzyme replacement therapy.  Adv Nephrol Necker Hosp. 2001;  31 317-339
• 113 Spada M, Pagliardini S, Yasuda M et al. High incidence of later-onset fabry disease revealed by newborn screening.  Am J Hum Genet. 2006;  79 31-40
• 114 Hoffmann B, Beck M, Rolfs A et al. [Fabry disease – complex clinical picture, simple diagnosis procedure, causal treatment].  Dtsch Med Wochenschr. 2008;  133 1965-1972; quiz 1973–1974
• 115 Rolfs A, Bottcher T, Zschiesche M et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.  Lancet. 2005;  366 1794-1796
• 116 Crutchfield K E, Patronas N J, Dambrosia J M et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.  Neurology. 1998;  50 1746-1749
• 117 Mitsias P, Levine S R. Cerebrovascular complications of Fabry’s disease.  Ann Neurol. 1996;  40 8-17
• 118 Mehta A, Beck M, Eyskens F et al. Fabry disease: a review of current management strategies.  QJM. 2010;  103 641-659
• 119 Eng C M, Guffon N, Wilcox W R et al. Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease.  N Engl J Med. 2001;  345 9-16
• 120 Ginsberg L, Manara R, Valentine A R et al. Magnetic resonance imaging changes in Fabry disease.  Acta Paediatr Suppl. 2006;  95 57-62
• 121 Fellgiebel A, Muller M J, Ginsberg L. CNS manifestations of Fabry’s disease.  Lancet Neurol. 2006;  5 791-795
• 122 Kurth T, Kase C S, Berger K et al. Smoking and risk of hemorrhagic stroke in women.  Stroke. 2003;  34 2792-2795
• 123 Kurth T, Kase C S, Berger K et al. Smoking and the risk of hemorrhagic stroke in men.  Stroke. 2003;  34 1151-1155
• 124 Reynolds K, Lewis B, Nolen J D et al. Alcohol consumption and risk of stroke: a meta-analysis.  JAMA. 2003;  289 579-588
• 125 Caplan L R, Hier D B, Banks G. Current concepts of cerebrovascular disease – stroke: stroke and drug abuse.  Stroke. 1982;  13 869-872
• 126 Brust J CM. Stroke and Substance Abuse.. In: Caplan L Uncommon Causes of Stroke.. Cambridge: Cambridge Medicine; 2008
• 127 Miyakis S, Lockshin M D, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
• 128 Hughes G R. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.  Br Med J (Clin Res Ed). 1983;  287 1088-1089
• 129 Vila P, Hernandez M C, Lopez-Fernandez M F et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.  Thromb Haemost. 1994;  72 209-213
• 130 Janardhan V, Wolf P A, Kase C S et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study.  Stroke. 2004;  35 736-741
• 131 Rafuse P E, Canny C L. Initial identification of antinuclear-antibody-negative systemic lupus erythematosus on ophthalmic examination: a case report, with a discussion of the ocular significance of anticardiolipin (antiphospholipid) antibodies.  Can J Ophthalmol. 1992;  27 189-193
• 132 Crowther M A, Ginsberg J S, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.  N Engl J Med. 2003;  349 1133-1138
• 133 Levine S R, Brey R L, Tilley B C et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.  JAMA. 2004;  291 576-584
• 134 Raupp M. Juvenile Schlaganfälle und deren Veränderung über die Zeit – Dissertation. Freiburg im Breisgau; 2006
• 135 Jacobs B S, Boden-Albala B, Lin I F et al. Stroke in the young in the northern Manhattan stroke study.  Stroke. 2002;  33 2789-2793
• 136 Chant H, McCollum C. Stroke in young adults: the role of paradoxical embolism.  Thromb Haemost. 2001;  85 22-29
• 137 Hagen P T, Scholz D G, Edwards W D. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.  Mayo Clin Proc. 1984;  59 17-20
• 138 Jones E F, Calafiore P, Donnan G A et al. Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly.  Am J Cardiol. 1994;  74 596-599
• 139 Klotzsch C, Janssen G, Berlit P. Transesophageal echocardiography and contrast-TCD in the detection of a patent foramen ovale: experiences with 111 patients.  Neurology. 1994;  44 1603-1606
• 140 Bendixen B H, Posner J, Lango R. Stroke in young adults and children.  Curr Neurol Neurosci Rep. 2001;  1 54-66
• 141 Pezzini A, Del Zotto E, Magoni M et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale.  Stroke. 2003;  34 28-33
• 142 Cramer S C, Rordorf G, Maki J H et al. Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study.  Stroke. 2004;  35 46-50
• 143 Leon L, Giannoukas A D, Dodd D et al. Clinical significance of superficial vein thrombosis.  Eur J Vasc Endovasc Surg. 2005;  29 10-17
• 144 Unno N, Mitsuoka H, Uchiyama T et al. Superficial thrombophlebitis of the lower limbs in patients with varicose veins.  Surg Today. 2002;  32 397-401
• 145 Mohr J P, Thompson J L, Lazar R M et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.  N Engl J Med. 2001;  345 1444-1451
• 146 Homma S, Di Tullio M R, Sacco R L et al. Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study.  Stroke. 1994;  25 582-586
• 147 McGaw D, Harper R. Patent foramen ovale and cryptogenic cerebral infarction.  Intern Med J. 2001;  31 42-47
• 148 Wu L A, Malouf J F, Dearani J A et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options.  Arch Intern Med. 2004;  164 950-956
• 149 Berlit P. Klinische Neurologie. 2. aktualisierte Auflage. Heidelberg: Springer Verlag; 2005